Stellaromics Inc.
Ye Fu is a highly experienced biotechnology professional, currently serving as Chief Technology Officer and Co-Founder of Stellaromics Inc., where innovative technology captures high-resolution 3D multi-omic data from tissue samples. In addition to this role, Ye Fu holds positions as Interim Chief Technology Officer and Board Member at Sedec Therapeutics, focusing on autoimmune and immune-oncology therapeutics, and as a Consultant and Director of Innovation at Aferna Bio, developing technologies for agriculture. Past experience includes serving as Principal at Plaisance Capital Management LLC and conducting postdoctoral research at Harvard University and The University of Chicago, specializing in DNA and RNA modifications and epigenetic studies. Educational credentials include a Bachelor of Science in Chemistry from Peking University and a doctoral degree from the University of Chicago.
This person is not in the org chart
This person is not in any teams
Stellaromics Inc.
Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations. Stellaromics is currently in the advanced stages of developing its Plexa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases. For comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.